We launched 1717 LSV in March 2018 to translate scientific results into patients benefits by filling the operational and financial gaps between the invention of radiopharmaceutical substances and their first clinical trials. We are focused, but not limited, to oncology indications to apply the full concept of Theranostics.

We believe that scientific and clinical guidance, financial expertise, and a sustainable organizational setup are instrumental to the success of young radiopharmaceutical companies. We can give strong support during the long journey to become an attractive license candidate for larger pharmaceutical companies. Our broad network of pre-clinical, clinical and manufacturing collaborators will help our partners to add maximum value at minimal costs to their projects.

As the former team of a successful early-stage radiopharmaceutical company we have experienced the importance to have access to the right support at the right time. That’s why we offer our in-depth operational support to promising young radiopharmaceutical ideas.

For investors, we will serve as an opportunity finder to built a platform to invest in these medium risk/high return radiopharmaceutical ventures on a deal by deal basis.

With our support in product development we add value to standard clinical care, which will help to bring patients in need true personalized new modern therapies.